PriMED Clinical Research obesity/overweight study for those with type II diabetes

Study Name: J2V-MC-GZLF A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Purpose:

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes

If you have the following, you could be eligible for this study:

  • Have type 2 diabetes
  • Have an HbA1c ≥7.5% to ≤10.5% at screening
  • Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
    • Diet and exercise
    • Stable dose of metformin
    • Sodium-glucose cotransporter-2 (SGLT2) inhibitor
  • Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening
  • Have a BMI of 27 or greater at screening

 

Location: PriMED Clinical Research

FAQs

We believe this study will potentially benefit our patients and future patients.

Participants who qualify for this study:

  • Are 18 years or older.
  • Have a diagnosis of high blood pressure.
  • Have a diagnosis of overweight or obesity (BMI of 25 or more).

This study will take about 70 weeks to complete.

Study activities may occur at the study doctor’s office, your home, or other locations as specified for the study and as allowed by local law.

The study doctor will talk to you about the specifics for this study, covering topics such as:

  • What current treatments can you continue
  • How the study will be done, including what will be needed from you
  • Answering any of your questions
  • Small amounts of blood will be obtained from you for testing and monitoring purposes

Participants may receive compensation for their time and travel.

Visits will be located at our PriMED Clinical Research office:

PriMED Clinical Research
3080 Ackerman Blvd, Suite 210
Dayton, Ohio 45429

If you are interested in learning more about how to sign up for the PriMED Clinical Research Hypertension Study, please call (937) 534-4201 and speak to a member of the research team, or simply fill out our online interest form

Prequalify for Clinical Research